BLTE Stock Forecast & Price Target

Belite Bio is a clinical-stage biopharmaceutical company with a strong pipeline, including its lead product candidate, Tinlarebant, for Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA). The company recently submitted an NDA in Japan through the Sakigake pathway and is awaiting FDA approval in the US with a potential commercial launch in March 2027. The company has a strong financial position, with a cash balance of ~$780 million and plans to target ~100 inherited-retinal-disease (IRD) specialists, 3,000 retina specialists, and 2,900 other ophthalmologists and optometrists for the launch of Tinlarebant. With a first-mover advantage in a market with a high unmet need and potential peak sales of ~$6 billion in the US and ~$700 million in Japan, we reiterate our Buy rating and raise our 12-month price target to $303.

Belite Bio is facing challenges with its lead candidate, Tinlarebant, in the treatment of Stargardt disease (STGD1) and Geographic Atrophy (GA). While it showed promising results in Phase 3 clinical trials, there are concerns about regulatory requirements and potential competition in the market. Furthermore, the company's financial position is uncertain, and its success will depend on launch execution and market access efforts.